A newly published study in Scientific Reports reveals that marine-derived compounds from starfish—specifically cucumarioside C1 (CuC1)—could help combat drug-resistant forms of prostate cancer.
Researchers tested CuC1, along with related compounds pacificusoside C (PaC) and cucumarioside C2 (CuC2), against multiple prostate cancer cell models, including those resistant to standard treatments like docetaxel.
Prostate cancer affects over 1.3 million men worldwide each year, and while initial treatments such as androgen deprivation therapy and AR pathway inhibitors offer temporary control, tumors often evolve into treatment-resistant variants. This study aimed to find new therapeutic strategies for these aggressive forms.
CuC1, extracted from the starfish Solaster pacificus, stood out as the most effective compound. It delivered strong cytotoxic effects across a range of prostate cancer models, including hormone-resistant and drug-resistant cells.
Notably, CuC1 remained effective even in cells that had developed resistance to conventional chemotherapy drugs—indicating it bypasses major resistance mechanisms like P-glycoprotein (P-gp) drug efflux.
In addition to its cytotoxicity, CuC1 affected key survival signaling pathways in cancer cells. It inhibited ERK1/2 and p38—two kinases often linked to therapy resistance—while simultaneously triggering apoptotic and necroptotic death mechanisms.
These findings suggest that CuC1 disrupts cancer cell survival through multiple routes, offering a potential way to prevent or delay resistance development.
Even more promising, when CuC1 was combined with standard chemotherapies such as cisplatin or docetaxel, researchers observed synergistic effects, especially at higher concentrations. This suggests CuC1 could enhance existing treatments rather than replace them, potentially improving outcomes for patients with advanced, drug-resistant prostate cancer.
However, researchers caution that CuC1 and its analogs also showed some toxicity to normal cells, meaning they are not yet selective enough for clinical use. Further studies, especially in living organisms, are needed to evaluate their safety and therapeutic potential.
This early-stage research highlights the untapped promise of marine natural products in oncology. If further validated, these starfish-derived compounds could become a valuable addition to the fight against one of the most lethal cancers affecting men worldwide.
